|
|
Intra-Abdominal (Visceral) Fat
|
|
|
Abdominal obesity:
|
|
|
High waist circumference
|
|
|
Slide 5
|
|
|
The Metabolic Syndrome:
|
|
|
Increased CAD Events in Metabolic Syndrome
|
|
|
Adipose Tissue:A Major Secretory Organ
|
|
|
Dyslipidaemia in Type 2 Diabetes and Metabolic Syndrome
|
|
|
Characteristics of LDL Subclasses
|
|
|
The Absolute Concentration of LDL-C C
|
|
|
LDL Subfractions “Control” vs Patient with Insulin Resistance
|
|
|
UKPDS:Risk Factors for MI.
|
|
|
|
CHD Prevention Trials with Statins in Diabetic Patients Subgroup Analyses.
|
|
|
Time to First Major Cardiovascular Event Patients With DiabetesTNT Study
|
|
|
Acute Coronary Syndromes and Diabetes.
|
|
|
Implications of Recent Trials Adult Treatment Panel III GuidelinesDiabetes
|
|
|
TNT Study
|
|
|
TNT Time to First Major Cardiovascular Event Patients With Metabolic Syndrome
|
|
|
CARDS:Collaborative AtoRvastatin Diabetes Study
|
|
|
Median Lipid Levels by Treatment
|
|
|
Median Lipid Levels by Treatment
|
|
|
CARDS
|
|
|
Treatment Effect on Primary Endpoint in CARDS
|
|
|
Cumulative Hazard for Stroke
|
|
|
Cumulative Hazard for Primary Endpoint in Older People
|
|
|
|
|
Joint British Societies’ Guidelines
|
|
|
|
CARDS: Safety Overview
|
|
|
CARDS: Safety Overview
|
|
|
CARDS: Safety OverviewMuscle-related Adverse Events
|
|
|
CARDS: Safety OverviewMuscle-related Adverse Events
|
|
|
|
|
Share this page with your colleagues and friends: